

**The Utah Society of Health System Pharmacists, University of Utah Hospitals and Clinics Present:  
2015 Resident Continuing Pharmacy Education Series**

**Target Audience:** Pharmacists, pharmacy technicians, pharmacy students, and other health professionals.

Date	Time & Location	Presenter	Title, Objectives & ACPE UAN
3/10 Tue.	HSEB 4100B at 3:00 pm	Brian K. Fung, PharmD,  Mentors: Adam Bress, PharmD, MS and Daniel M. Witt, PharmD, FCCP, BCPS	<p style="text-align: center;"><b>Optimizing Fate: Pharmacogenomics in Clinical Practice – 0167-0000-15-200-L04-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the utility of the CPIC guidelines and their recommendations</li> <li>2. Apply the CPIC guidelines to two medications that are actionable if genetic information is available</li> <li>3. Assess the current barriers for implementing pharmacogenomics into clinical practice</li> <li>4. Propose a method for leveraging informatics to facilitate the adoption of pharmacogenomics</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize that genetic variations can influence how individuals respond to drugs.</li> <li>2. Recognize that drug dosing may need to be tailored for certain medications based on an individual's genetic variation.</li> <li>3. Identify two medications that are actionable if genetic information is available.</li> </ol>
3/10 Tue.	HSEB 4100B at 4:00 pm	Bhanupriya Sirandas, PharmD  Mentor: Nicole Kenyon, PharmD, BCPS	<p style="text-align: center;"><b>From Chronic to Curable: Treating Hepatitis C in Post Transplant Recipients – 0167-0000-15-201-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Discuss the importance of treating recurrent Hepatitis C in post transplant patients</li> <li>2. Identify current targets of therapies utilized to treat Hepatitis C in post transplant patients</li> <li>3. Compare and contrast past and current therapies for Hepatitis C in post transplant patients</li> <li>4. Develop a treatment plan for a post-transplant recipient with Hepatitis C</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Identify various genotypes of Hepatitis C</li> <li>2. Recognize testing used to diagnose Hepatitis C</li> <li>3. List a consequence of Hepatitis C recurrence post liver transplant</li> </ol>
3/12/ Thur.	HSEB 2110 At 3:00 pm	Trang Au, PharmD  Mentor: Steve Kirkegaard, PharmD	<p style="text-align: center;"><b>Nauseated, Not Psychotic: Novel Use for Olanzapine – 0167-0000-15-003-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe chemotherapy-induced nausea and vomiting (CINV)</li> <li>2. Review the clinical uses of olanzapine</li> <li>3. Evaluate evidence for olanzapine for CINV</li> <li>4. Design an anti-emetic regimen for a patient using the National Comprehensive Cancer Network guidelines</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Review the formulations of olanzapine</li> <li>2. Differentiate FDA-approved indications versus off- label uses for olanzapine</li> <li>3. Compare the cost of olanzapine with other anti-emetic agents</li> </ol>

3/12/ Thur.	HSEB 2110 At 4:00 pm	Jordan McPherson, PharmD  Mentor: Sara Hiller, PharmD	<p style="text-align: center;"><b>I Know What You Approved Last Summer: 2014 New Oncology Drug Update – 0167-0000-15-208-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Identify the FDA approved indications of the oncology drugs approved in 2014</li> <li>2. Describe the mechanism of action and adverse events associated with the newly approved oncology drugs</li> <li>3. Evaluate potential drug interactions for the newly approved oncology drugs</li> <li>4. Distinguish the place in therapy of the newly approved oncology drugs as related to current standards of care</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Match brand names with generic names for the oncology drugs approved in 2014</li> <li>2. Recognize product formulations and costs of the newly approved oncology drugs</li> <li>3. Describe proper storage and preparation procedures of the newly approved oncology drugs</li> </ol>
3/17 Tue.	HSEB 4100B at 3:00 pm	John Schoen, PharmD  Mentors: Erin Fox, PharmD Russell Benefield, PharmD	<p style="text-align: center;"><b>Weight-Based Medications in Obesity: Should We Scale Back? – 0167-0000-15-205-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the pharmacokinetics changes that occur in obesity</li> <li>2. Discuss the importance of weight-based dosing in obesity</li> <li>3. Formulate a strategy to determine how to appropriately dose a weight-based medication for an obese patient</li> <li>4. Select an appropriate body weight for the medication(s) discussed in the case example(s)</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Discuss the importance of weight-based dosing in obesity</li> <li>2. Describe the different body weights used to dose weight-based medication</li> <li>3. List 5 medications that are dosed based on body weight</li> </ol>
3/17 Tue.	HSEB 4100B at 4:00 pm	Jessica Louie, PharmD  Mentor: Donald Alexander, PharmD	<p style="text-align: center;"><b>Filtering out the waste: exploring the utility of renal biomarkers in critically ill – 0167-0000-15-204-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the tools for assessing renal function in the past, present and future</li> <li>2. Differentiate advantages and disadvantages of renal biomarkers</li> <li>3. Explain why appropriate estimates of renal function are important to medication dosing</li> <li>4. Select an appropriate renal function assessment plan for a critically ill patient</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the tools for assessing renal function in the past, present and future</li> <li>2. List biomarkers available for assessing renal function</li> <li>3. Identify why renal function is important to medication dosing</li> </ol>
3/19 Thur.	HSEB 3515B at 3:00 pm	Hanna Bailey, PharmD  Mentor: Jeffrey Gilreath, PharmD, BCOP	<p style="text-align: center;"><b>Let's Iron Out the Kinks in Thalassemia – 0167-0000-15-206-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the two most common thalassemia forms based on genetic abnormalities</li> <li>2. Identify organs affected by iron overload</li> <li>3. Compare and contrast currently available iron chelators</li> <li>4. Construct a treatment strategy for a patient with iron overload</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Review currently available iron chelating agents</li> <li>2. Compare different administration methods for each iron chelator</li> <li>3. Recognize current issues involving procurement of iron chelators</li> </ol>

3/19 Thur.	HSEB 35150B at 4:00 pm	Natalee Tanner, PharmD  Mentor: Elizabeth Young, PharmD, BCPS	<p style="text-align: center;"><b>TSOACs in Cancer: Hop aboard the thrombus – 0167-0000-15-2007-L01-P/T</b></p> <p><u>Pharmacist Objectives</u></p> <ol style="list-style-type: none"> <li>1. Review the effect of active malignancies on a patient’s coagulopathy</li> <li>2. Assess guideline recommendations for venous thromboembolism (VTE) treatment in cancer patients with active malignancies</li> <li>3. Analyze the risk and benefits associated with the therapeutic options for VTE treatment in cancer patients with active malignancies</li> <li>4. Discuss the available data for the target specific oral anticoagulants (TSOACs) for VTE treatment in cancer patients with active malignancies</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Identify the medications used for the VTE in cancer patients with active malignancies</li> <li>2. Review the proper storage, handling, and dispensing of the therapeutic options for VTE in cancer patients with active malignancies</li> <li>3. Recognize cost differences between TSOACs and other anticoagulant options</li> </ol>
3/24 Tue.	HSEB 4100B at 3:00 pm	Lisa Hong, PharmD, BCPS  Mentors: Chad Condie, PharmD Benson Sederholm, PharmD, BCPS	<p style="text-align: center;"><b>Orthostatic Hyp-“Whoa!”-tension: Exploring Updates in Management – 0167-0000-15-203-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the pathophysiology of orthostatic hypotension</li> <li>2. Identify etiologies of orthostatic hypotension and determine medication-related causes</li> <li>3. Discuss the pharmacologic and non-pharmacologic options utilized in the treatment of orthostatic hypotension</li> <li>4. Given a patient case, evaluate treatment options and formulate a plan for management of orthostatic hypotension</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Define orthostatic hypotension and list signs and symptoms consistent with this diagnosis</li> <li>2. Explain non-pharmacologic options and recognize agents used to treat orthostatic hypotension</li> <li>3. Identify common side effects associated with medications used to treat orthostatic hypotension</li> </ol>
3/24 Tue.	HSEB 4100B at 4:00 pm	Jennifer Babin, PharmD, BCPS  Mentor: Krystal Moorman, PharmD, BCPS	<p style="text-align: center;"><b>Wide Awake: Management of Insomnia – 0167-0000-15-202-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe non-pharmacologic treatment options for insomnia</li> <li>2. Compare different medication classes used in the treatment of insomnia</li> <li>3. Analyze evidence for the use of the newest FDA-approved medication for insomnia, suvorexant</li> <li>4. Choose appropriate pharmacotherapy for insomnia given a patient scenario</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. List three over-the-counter and prescription medications used to treat insomnia</li> <li>2. Describe non-pharmacologic treatment options for insomnia</li> <li>3. Compare the cost of suvorexant to the cost of other medications used to treat insomnia</li> </ol>
3/26 Thur.	HSEB 4100B at 3:00 pm	Ashley Kosloske, PharmD  Mentor: Heidi Simons, PharmD	<p style="text-align: center;"><b>Not What you Were Expecting: Understanding Pharmacy’s Role in Managing Obstetric Emergencies – 0167-0000-15-210-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the physiologic changes that occur during pregnancy that can contribute to the development of obstetric emergencies.</li> <li>2. Differentiate between the preferred antihypertensive agents used in treating pre-eclampsia.</li> <li>3. Compare and contrast the role of magnesium sulfate versus other anticonvulsants in the management of eclampsia in pregnancy.</li> <li>4. Select an appropriate treatment plan for a patient that presents with postpartum hemorrhage.</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. State the role of methotrexate in ectopic pregnancy and recall the precautions that must be considered when handling this medication.</li> <li>2. List two potential adverse outcomes that can result from untreated pre-eclampsia.</li> <li>3. Describe the proper storage, preparation, and administration of the common medications used in the management of postpartum hemorrhage.</li> </ol>

3/26 Thur.	HSEB 4100B at 4:00 pm	Anastasia Diamantopoulos, PharmD  Mentor: Tyler Sledge, PharmD	<p style="text-align: center;"><b>Not your Run of the Mill Emergency: ROTEM® for Management of Bleeding – 0167-0000-15-209-L04-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the methodology and clinical application of ROTEM® analysis</li> <li>2. Illustrate the difference between conventional anticoagulation tests and ROTEM</li> <li>3. Interpret ROTEM® results with respect to drug therapy</li> <li>4. Assess therapeutic strategies in the management of patients based on ROTEM® results</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe why ROTEM® test is useful</li> <li>2. List other tests utilized in trauma to assess bleeding</li> <li>3. Explain common pharmacologic interventions that may affect the results of ROTEM</li> </ol>
4/07 Tue.	HSEB 4100B at 3:00 pm	Erica Marini, PharmD  Mentor: Linda Tyler, PharmD, FASHP	<p style="text-align: center;"><b>The Law and Ethics of an Ebola Cure – 0167-0000-15-211-L03- P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Analyze the legal measures that incentivize manufactures to develop treatments for rare diseases.</li> <li>2. Describe reasons why manufacturers did not develop an Ebola treatment prior to the 2014 outbreak.</li> <li>3. Analyze the ethical considerations involved in drug development during a global outbreak of disease.</li> <li>4. Evaluate the appropriateness of use of un-approved treatments during the Ebola outbreak.</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize laws that influence drug development for rare diseases.</li> <li>2. Describe the purpose of experimental trials in drug development.</li> <li>3. Discuss the potential dangers of using un-approved treatments.</li> </ol>
4/07 Tue.	HSEB 4100B at 4:00 pm	Tonya Smith, PharmD  Mentor: Christine Jamjian, PharmD	<p style="text-align: center;"><b>One Pill Fits All: Past, Present, and Future of Single Tablet Regimens for the Treatment of HIV – 0167-0000-15-212-L02-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the history and outgoing burden of human immunodeficiency virus (HIV).</li> <li>2. Recall the four FDA-approved single-tablet regimens (STRs) used to treat HIV.</li> <li>3. Compare and contrast potential drug-drug interactions, side effects, food requirements, and cost of the four STRs.</li> <li>4. Select an appropriate STR for a patient diagnosed with HIV.</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Understand the burden of HIV in the United States.</li> <li>2. Recognized brand and generic names of the four current STRs used to treat HIV.</li> <li>3. Compare and contrast various characteristics of STRs, including how to address cost barriers to accessing STRs.</li> </ol>

4/09 Thur.	HSEB 4100B at 2:00 pm	Abby Coleman, PharmD, MBA  Mentor: Katie Scerbo PharmD	<p style="text-align: center;"><b>Co-dependency gone wrong: Hepatorenal Syndrome – 0167-0000-15-213-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Interpret the clinical signs and symptoms of hepatorenal syndrome</li> <li>2. Compare and contrast treatment approaches based on the patient’s required level of care</li> <li>3. Understand how to monitor treatments used for hepatorenal syndrome</li> <li>4. Develop recommendations for the prevention of hepatorenal syndrome based on initial disease presentation</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Identify patients who are at high risk for developing hepatorenal syndrome</li> <li>2. List the drugs used in the management of hepatorenal syndrome</li> <li>3. Explain how the drugs used in hepatorenal syndrome are supplied and stored</li> </ol>
4/09 Thur.	HSEB 4100B at 3:00 pm	Jessica Hoyt, PharmD  Mentor: Anthony Dalpiaz, PharmD	<p style="text-align: center;"><b>Hepatitis C Ya Later: Game Changers in Medication Therapy – 0167-0000-15-214-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the epidemiology and complications of hepatitis C</li> <li>2. Compare the side effects, duration of therapy, sustained virologic response and cost of new pharmacologic therapies for hepatitis C</li> <li>3. Design an appropriate treatment plan for a treatment naïve patient with hepatitis C</li> <li>4. Identify resources for further information on hepatitis C therapy</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the clinical symptoms and consequences of hepatitis C</li> <li>2. Recognize medications that are currently marketed for the treatment of hepatitis C in the US</li> <li>3. Understand the financial barriers of the new therapeutic agents for hepatitis C</li> </ol>
<b>Saturday Session Requires Online Registration by April 3, 2015 to reserve your seat since seating is limited! Go to <a href="http://www.ushp.org">www.ushp.org</a> to register.</b>			
4/11 Sat.	HSEB 4100B at 8:00 am  (please arrive by 7:45 to sign in for this event)	Allison Arterbury PharmD  Mentor: Karen Gunning, PharmD	<p style="text-align: center;"><b>Sero-TUNE-in! An Update on Depressive Disorders – 0167-0000-15-004-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Review the mechanisms of action of the different available classes of antidepressants</li> <li>2. Discuss the first line pharmacological treatments for major depressive disorder (MDD)</li> <li>3. Describe the dosing strategies for the 3 new antidepressants approved in the past 3 years</li> <li>4. Differentiate advantages and disadvantages of the different pharmacologic options available to treat MDD</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. List the brand and generic names of antidepressants approved in the last 3 years</li> <li>2. Recognize the different classes of antidepressants available</li> <li>3. Evaluate the cost differences and potential insurance issues that may arise with different antidepressants</li> </ol>

4/11 Sat.	HSEB 4100B at 9:00 am	Lauren Holesh, PharmD  Mentor: Linda Tyler, PharmD, FASHP	<p align="center"><b>FDA OTC Regulation: A Tale of Two Tracks – 0167-0000-15-219-L03-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Outline the models used to assess the safety of new non-prescription medications</li> <li>2. Compare and contrast the two processes used to regulate OTC products</li> <li>3. Evaluate the implications of an OTC drug regulated through each approval process</li> <li>4. Assess the areas for future development of new safety measures from the FDA</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Define the categories historically used to classify the safety of OTC products</li> <li>2. List three drugs regulated by both the New Drug Approval process and the Monograph process</li> <li>3. Understand the difference between the two methods used to regulate OTC products</li> </ol>
4/11 Sat.	HSEB 4100B at 10:10 am	Alisyn Hansen PharmD  Mentor: Karen Gunning, PharmD	<p align="center"><b>Shared Decision Making: Medication Discontinuation in Geriatric Patients – 0167-0000-15-218-L05-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize potentially inappropriate medications in older adults.</li> <li>2. Differentiate goals of chronic disease state management for older patients compared to a younger population.</li> <li>3. Assess medications used for prevention in older patients and understand their time to benefit.</li> <li>4. Use shared decision making to help patients and caregivers weigh risks vs benefits of medication therapy.</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Define functional versus chronological age in the context of geriatric care.</li> <li>2. Recognize potentially inappropriate medications in older adults and understand why certain medications are not covered by insurance providers.</li> <li>3. Explain which over-the-counter medications should be avoided in older adults.</li> </ol>
4/11 Sat.	HSEB 4100B at 11:10 am  (Followed by time to purchase lunch on your own.)	William Black, PharmD, MBA  Mentor: Kavish Choudhary, PharmD, MS	<p align="center"><b>You have no idea how high I can fly: advancing the role of the pharmacy technician – 0167-0000-15-216-L04-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the advanced roles in which pharmacy technicians are currently involved in the state of Utah</li> <li>2. Understand the barriers to implementing advanced roles for pharmacy technicians</li> <li>3. Evaluate the impact that expanded pharmacy technician roles will have on the role of a pharmacist</li> <li>4. Distinguish technicians with proper training and/or experience required to carry out an advanced role</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe the advanced roles in which pharmacy technicians are currently involved in the state of Utah</li> <li>2. List areas for potential expansion of pharmacy technician roles</li> <li>3. Recognize the barriers to implementing advanced roles for pharmacy technicians</li> </ol>
4/11 Sat.	HSEB 4100B at 1:00 pm	Nicole Caffiero, PharmD  Mentor: Karen Gunning, PharmD	<p align="center"><b>Long Acting Reversible Contraceptives: Are we breeding confusion with long acting reversible contraceptives? – 0167-0000-15-217-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Compare and contrast the different LARC options, including mechanism of action, administration, associated risks, and monitoring parameters.</li> <li>2. Evaluate the efficacy of different long acting reversible contraceptive agents.</li> <li>3. Discuss the place in therapy of LARCs in adolescents and impact of LARCs on teen births as well as evaluating the law relevant to treating minors with LARCS.</li> <li>4. Prepare effective counseling techniques for patients and parents using LARCs.</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Identify and define the different LARC options</li> <li>2. State the patients that LARCs may be an appropriate contraceptive option as well as evaluate the laws relevant to treating minors with LARCs</li> <li>3. Discuss the impact of LARCs on teen births</li> </ol>

4/11 Sat.	HSEB 4100B At 2:00 pm	Eve Van Wagoner, PharmD  Mentors: Krystal Moorman, PharmD, BCPS McKay Robinson, PharmD	<p align="center"><b>ACE-I in the hole: Should ACE-I be prescribed for all diabetic patients regardless of blood pressure status? – 0167-0000-15-221-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Describe how ACE-I and ARBs work within the RAS System</li> <li>2. Explain how microalbuminuria indicates kidney damage and leads to cardiovascular disease</li> <li>3. Compare options to prevent or slow the progression of microalbuminuria</li> <li>4. Develop a medication therapy plan for a normotensive, type 2 diabetic patient with/without microalbuminuria</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Understand how ACE-I and ARBs work with the RAS system</li> <li>2. List 5 ACE-I and/or ARBs</li> <li>3. Define microalbuminuria</li> </ol>
4/11 Sat.	HSEB 4100B At 3:00 pm	Kelsey Palmer, PharmD  Mentor: Patricia Jerant, PharmD, BCPS	<p align="center"><b>Weight Loss Drugs: The Skinny on the Available Agents – 0167-0000-15-220-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Review the history of weight loss medications and the factors that contributed to the removal of certain agents from the market</li> <li>2. Identify patients who are candidates for weight loss agents</li> <li>3. Describe common side effects and contraindications associated with weight loss agents</li> <li>4. Compare and contrast available agents for weight loss</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize the risks associated with currently available weight loss agents and those previously removed from the market</li> <li>2. List 3 prescription agents available to weight loss</li> <li>3. Understand the controlled substance classification of the available weight loss agents</li> </ol>

**Registration, Info & Fees:** All classes are one hour. The cost is \$60 for pharmacists and \$20 for technicians to attend regardless of the number of hours attended, and this fee can be paid online at [www.ushp.org](http://www.ushp.org). No RSVP is required for the weekday sessions, but registration for the Saturday event on 4/11 is required to ensure a sufficient number of handouts are printed. Seating is limited. To receive CE (Continuing Education) credit, you must be a USHP member. If you are interested in joining USHP, please visit our website [www.ushp.org](http://www.ushp.org) and join online.

**Credit Hours:** Through attending this program, up to 23.0 contact hours (0.23 CEUs) can be attained. Participants must be a member of USHP, sign in at each program, complete evaluation forms, complete and pass the post-test with a 75% or better, and complete an Attendance Verification Form at the conclusion of all programs.

**Special Accommodations:** If you are in need of any special accommodation, please contact us a minimum of 2 days prior to the program in order to make arrangements at the below listed contact.

**Commercial Support:** No commercial support was received for this program.

**Questions?** Contact Shantel Mullin at [shantel.mullin@hsc.utah.edu](mailto:shantel.mullin@hsc.utah.edu) or (801) 587-3966.



The Utah Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.